Legal status · United States
Is Apraglutide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Apraglutide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Apraglutide in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | In development for short bowel syndrome with intestinal failure. Teduglutide, the daily GLP-2 analogue, is separately approved as Gattex. |
| FDA approval status | Investigational for short bowel syndrome. Not approved at the time of this review. |
| Human studies cited | 2 of 2 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Apraglutide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Apraglutide is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Apraglutide is
A once-weekly GLP-2 analogue for short bowel syndrome, where teduglutide requires a daily injection. Improved fluid absorption in its phase 2 metabolic balance studies.
GLP-2 is the gut's own repair signal, and it is the one proglucagon product with an approved drug behind it: teduglutide, for short bowel syndrome with intestinal failure. The limitation is that teduglutide is injected daily, in a population already managing parenteral nutrition.
Mechanism: A long-acting analogue of glucagon-like peptide-2, a 33-amino-acid proglucagon product released from intestinal L cells. GLP-2 acts on the intestinal epithelium to increase mucosal growth, villus height and crypt depth, slow gastric emptying and transit, and increase intestinal blood flow, which together raise absorptive capacity.
Regulatory history: Investigational for short bowel syndrome. Not approved at the time of this review.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Apraglutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Apraglutide in other countries
Frequently asked questions
Is Apraglutide legal in the United States?
No. Apraglutide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: In development for short bowel syndrome with intestinal failure. Teduglutide, the daily GLP-2 analogue, is separately approved as Gattex.
Can I buy Apraglutide in the United States?
No approved product exists to buy. In the United States Apraglutide is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: In development for short bowel syndrome with intestinal failure. Teduglutide, the daily GLP-2 analogue, is separately approved as Gattex.
Is Apraglutide FDA approved?
No. FDA status: Investigational for short bowel syndrome. Not approved at the time of this review.. Current US classification: "Investigational, not approved". On the evidence, 2 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Apraglutide live on its compound profile.
Apraglutide profileThis page is general information about the regulatory status of Apraglutide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.